SoCal TBA May In-Person Coffee Chat: Flying to academia in the US – Roadmap to professorship5/13/2022 Speaker: Dr. Chih-Ying Su, Associate Professor in the Section of Neurobiology, Division of Biological Sciences at UC San Diego Time: May 21, Saturday, 2022, 10:00 ~12:00 AM Location: Bella Vista Social Club & Caffe https://goo.gl/maps/M9ifYDF9bvVDVijW8 Register Link: https://socaltba-may-coffee-chat.eventbrite.com 南加州台灣生技協會五月份 Coffee Chat *本活動將以中文舉行,歡迎各領域的朋友、計畫申請教職的博士班學生和博士後參加。 如何在美國競爭激烈的學術圈中脫穎而出,成為研究型大學的終生職教授?研究之路踽踽獨行,如何調整心態,做好時間管理?非英語母語者又該如何加強口頭報告及寫作論文的技巧,將研究成果傳達給他人? SoCal TBA 本次榮幸邀請到美國加州大學聖地牙哥分校生命科學院的蘇稚盈副教授(Dr. Chih-Ying Su)來與我們喝咖啡。蘇教授著重神經科學基礎研究,專精於嗅覺受體神經元如何接受不同氣味的訊息,研究成果發表在《Nature》、《Science》、《PNAS》等著名期刊。本次活動她將分享:
Do you know how to land a job in academia in the US? Are you currently a Ph.D. student feeling a bit stressed out? Or are you a postdoc planning to apply for academic jobs? Come join us for our Coffee Chat on May 21. Dr. Su will share her life story from an international graduate student to a UCSD professor. Let’s learn from her experience and tips for you to succeed in your pursuit of Ph.D. and academic positions. In this event, she will discuss:
Speaker Bio Dr. Chih-Ying Su is an Associate Professor in the Section of Neurobiology, Division of Biological Sciences at UC San Diego. She received her B.A. in Zoology from National Taiwan University and Ph.D in Neuroscience from Johns Hopkins University School of Medicine. She conducted her postdoctoral research with Dr. John Carlson at Yale University. Dr. Su’s laboratory focuses on addressing how olfactory receptor neurons (ORNs) process odor information since these neurons are the primary source of sensory input. Their current research topics include: (1) how compartmentalization allows insect ORNs to process information through ephaptic interaction, and (2) how neuromodulation can act on ORNs to regulate responses and influence odor-guided behaviors in Drosophila. Dr. Su has been the recipient of a Mette Strand Young Investigator Award. She and her colleagues have published research articles in prestigious journals including Science, Nature, PNAS, Nature Communications, Current Biology, eLife and Neuron. This event is proudly sponsored by the Science and Technology Division, Taipei Economic and Cultural Office in Los Angeles.
0 Comments
Speaker: Dr. Kuo-Shyan Lin, Associate Professor at University of British Columbia
Time: May 14, Saturday, 2022 at 5-6.10 pm (PST) 8-9.10 pm (EST) May 15, Sunday, 2022 at 8-9.10 am (Taiwan time) Location: On-line via Zoom Registration Link: https://socaltba-may-online-event.eventbrite.com 會議連結將在活動前寄出,我們期待您的參與! 在癌症治療中,除了大家熟知的化療、標靶藥與現在當紅的免疫療法外,放射線療法也是被廣為使用,過往的放射線療法較難以精準定位到腫瘤,仍會造成周邊細胞一定程度的損傷。然而,近年在核醫影像藥物, ,開發上有了大幅的突破,能夠有效改善過去放射線療法的缺點, 並且達到所謂精準腫瘤科學 (Precision Oncology)。結合高專一性的標靶與高敏感度的正子造影 (PET)技術,近年來美國藥品監督管理局FDA通過核醫影造影劑與治療劑針對PSMA於前列腺癌的診斷與治療,因此開啟了眾多新創公司針對前列腺特異性膜抗原 (PSMA) 標記開發不同的放射診斷治療 Theranostics 藥物開發的競賽。 SoCal TBA 本次榮幸邀請在加拿大溫哥華UBC 及 BC Cancer 擔任副教授兼資深研究員的林國賢博士 (Kuo-Shyan Lin) 主講。林博士擁有豐富的核醫影像藥物開發的經歷,並專精於前列腺特異性膜抗原 (PSMA) 影像對於前列腺内的腫瘤定位、治療分期和治療成果追蹤之研究。本次活動中他將分享自身在PSMA核醫藥物開發的歷程。 從他的演講你將會了解:
Speaker Bio Dr. Kuo-Shyan Lin studied nuclear engineering and health physics at the National Tsing Hua University in Hsinchu, Taiwan. He then undertook his doctoral and postdoctoral training in radiochemistry at Johns Hopkins University in Baltimore. After continuing his work as a Research Associate at the Brookhaven National Laboratory in New York, and then as an Assistant Professor at the University of Pittsburgh, Dr. Lin joined the BC Cancer, part of the Provincial Health Services Authority, (BC Cancer) in 2009, to set up the radiopharmaceutical development program at its newly established cyclotron facility. He is currently an Associate Professor in the Department of Radiology at UBC, and a Senior Scientist in the Department of Molecular Oncology at BC Cancer. He also heads the Radiochemistry Program at BC Cancer to develop novel radiopharmaceuticals for cancer diagnosis and therapy. He recently received Canadian Institutes of Health Research funding to design new radiopharmaceuticals to improve the management of clear cell renal cell carcinoma. Dr. Lin's research focuses on developing novel radiopharmaceuticals for cancer diagnosis and therapy. The Lin lab is actively developing novel radiopharmaceuticals to improve cancer diagnosis and therapy. Current research efforts focus on (1) the development of novel radiopharmaceuticals targeting various potential markers expressed on cancer cell membranes; (2) the application of albumin binder to improve tumor uptake of radiotherapeutic agents; and (3) the application of cleavable linkers to reduce kidney uptake of peptide radiopharmaceuticals. SoCal TBA April In-Person Coffee Chat - Career Insights from Life Science Industry Consultant5/8/2022 南加州生技協會四月份 Coffee Chat
Speaker: Dr. Anthony Tsai, Lead Consultant at Tsai Consulting Time: April 17th 3-4:30pm Location: Hidden House Coffee- Santa Ana (https://hiddenhousecoffee.com/pages/visit) 511 E Santa Ana Blvd, Santa Ana, CA 92701 Register Link: https://socaltba2022aprcc.eventbrite.com 在廣闊的科學方向曾經感到迷惘過嗎? 跟著時代的變化科學研究也在很快速的在改變、有很多新的研究領域可以探索。 有些人因為這個改變會煩惱要選什麼研究方向或是會想要切換領域。加入我們一起與蔡博士喝杯咖啡吧!他具有液態活檢, 生物傳感器, 癌症分子分析, 再生醫學和儀器的研究與顧問的經驗!! 蔡博士很樂意分享他從Hitachi Science研究經驗到他現在當生科顧問的工作路程,也能回答任何人生方面的問題:
Ever feel lost in the vast research directions in the science industry? Science research has been growing exponentially with different focuses for scientists to explore. Because of the rapid changes and new discovery, some may have trouble deciding their focus, and some might want to shift their field. Join our coffee chat with Dr. Anthony Tsai, who has experience in research and consulting in liquid biopsy, biosensor, cancer molecular analysis, and regenerative medicine!! Dr. Tsai can share his career development from a research-related position in Hitachi Science to a Life Science consultant for multiple industries, and answer any questions you may have on:
Speaker Bio Dr. Tsai received his Ph.D in Materials Sciences from UC Irvine. He has combined 11 years of experience in miniaturized electrochemical, cancer biomarker, FDA De Novo, leadership and management, which allowed him to become a self-employed lead consultant for FDA regulations, healthcare market analysis, and other consulting services. 南加州生技協會三月份線上活動:神經科學家的機會與挑戰 Speaker: 黃正球 (Cheng-Chiu Joe Huang), Director and Project Lead of Neuroscience NGTx at Eli Lilly Time: Mar 26, 2022 11 AM Pacific Time (US and Canada) Registration Link: https://socaltba2022marcc.eventbrite.com 隨著合成生物學以及基因編輯技術的演進,以及人工智慧的興起,神經科學正在廣納跨領域的知識而呈現嶄新的樣貌,近年來在基礎研究的各種進展,是否也讓各種神經疾病的治療帶來新的契機? SoCal TBA 本次榮幸邀請到在Eli Lilly Neuroscience NGTx 擔任Director and Project Lead的黃正球博士(Cheng-Chiu Joe Huang) 主講。黃博士擁有豐富的學術研究經歷,其成果曾刊登於著名期刊(Nature Medicine, Neuron等),以及具有開發神經退化性疾病和疼痛管理藥物的經驗。本次活動中他將分享自身在產學界的歷程,也會與我們一同探討神經科學在生醫製藥的展望。你不會想錯過:
Speaker Bio Dr. Cheng-Chiu (Joe) Huang, a Ph.D. in Developmental Biology and Neuroscience, has extensive experience working on preclinical animal models, in vivo pharmacology, early clinical development, and project management in both academia and the biotech industry. His track record of innovations in genetic medicine (RNA and Gene Therapy) for neurological and immunological diseases includes not only his publications about genetic and viral tools development for sensory disorders, but also multiple discovery programs in neuro-immune interactions, autonomic hyperreflexia, and immuno-oncology. After transitioning into industry, he has also managed a pipeline project in postsurgical pain management toward Investigational New Drug Application (IND) application and successful clinical development. Dr. Huang has also established his management and leadership roles across different stages in his career. Supervising junior scientists in academia, he served as the director of cross-functional teams, with external partners and CROs on harnessing novel therapeutic modalities to tackle chronic pain and neurodegenerative diseases, and on building IP moat around the assets. He has been a senior scientific prospector of more than 30 due diligence activities in scouting assets and M&A targets ranging from preclinical to human phase 2 stages, and is currently the Director and Project Lead of Neuroscience NGTx at Eli Lilly. |
Archives
March 2023
Categories |